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Parkinson’s disease (PD) is a neurological disorder, associated with rigidity, bradykinesia,
and resting tremor, among other motor symptoms. In addition, patients with PD also
show cognitive and psychiatric dysfunction, including dementia, mild cognitive impairment
(MCI), depression, hallucinations, among others. Interestingly, the occurrence of these
symptoms—motor, cognitive, and psychiatric—vary among individuals, such that a
subgroup of PD patients might show some of the symptoms, but another subgroup does
not. This has prompted neurologists and scientists to subtype PD patients depending
on the severity of symptoms they show. Neural studies have also mapped different
motor, cognitive, and psychiatric symptoms in PD to different brain networks. In this
review, we discuss the neural and behavioral substrates of most common subtypes of
PD patients, that are related to the occurrence of: (a) resting tremor (vs. nontremor-
dominant); (b) MCI; (c) dementia; (d) impulse control disorders (ICD); (e) depression;
and/or (f) hallucinations. We end by discussing the relationship among subtypes of PD
subgroups, and the relationship among motor, cognitive, psychiatric factors in PD.
Keywords: Parkinson’s disease, tremor, dementia, mild cognitive impairment, hallucinations, depression, impulse
control disorders
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder charac-
terized by motor (bradykinesia, rigidity and resting tremor) and
non-motor symptoms, such as cognitive impairment, autonomic,
affective and behavioral disturbances (Jankovic, 2008). The com-
plex clinical picture of motor and non-motor symptoms is not
only different between PD patients, but is also changing along
the course of disease progression in each patient. The neurode-
generative nature of PD and its pharmacological management are
involved in this clinical heterogeneity. PD is characterized by a
progressive widespread diffusion of the Lewy body neuropathol-
ogy from subcortical to cortical structures (Braak et al., 2003);
therefore at different disease stages PD patients present different
loads of Lewy body neuropathology and different involvements
of subcortical and cortical structures. Moreover, drugs used to
manage clinical symptoms, as dopaminergic drugs (Bonuccelli
and Pavese, 2006; Poewe et al., 2010) have motor and non-
motor effects that change along disease progression (Poletti and
Bonuccelli, 2013).
Classifications of PD into different subtypes have been pro-
posed to reduce the heterogeneity of clinical features associated
with PD, and thus better investigate their neural correlates and
provide better treatment options. Two approaches are used to
achieve these classifications: empirically assigned or data-driven
(Marras and Lang, 2013). Empirically assigned classifications of
specific clinical motor and non-motor symptoms in PD patients
(e.g., rigidity, cognitive impairment, psychosis, impulse control
disorder (ICD), autonomic dysfunction) compare samples of
patients with vs. without the investigated clinical symptom; for
example, on the basis of the predominant motor symptoms
as indicated by the Unified Parkinson’s Disease Rating Scale
(UPDRS) motor subscores, PD patients were categorized into
patients with predominant postural instability and gait difficulty
and patients with predominant tremor (Jankovic et al., 1990). On
the other hand, the data-driven approach searches for variables
that group together each subtype without a-priori hypothesis;
for example the cluster analysis of Lewis et al. (2005) identi-
fied four subtypes of PD patients: (1) young onset; (2) non-
tremor dominant with cognitive impairment and depression; (3)
rapid progression without cognitive impairment; and (4) tremor
dominant.
The empirically assigned and the data-driven classification
approaches may identify partially overlapping subtypes (van
Rooden et al., 2010), as in the case of the motor subtypes pro-
posed by Jankovic et al. (1990) and clusters proposed by Lewis
et al. (2005). These approaches have been attempted for motor,
cognitive and psychopathological features of PD patients, while,
they have not been attempted on findings of neuropathological
and neuroimaging assessments.
A recent comparison of the empirically assigned and data
driven classification approaches (Marras and Lang, 2013) under-
lined how the former has the advantages of small number of
subtypes, ease of implementation and assignment of patients
to one or another subtype; on the contrary clusters derived
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from the data-driven approach are inherently more complicated,
incorporating more variables that are often not regularly mea-
sured in clinical practice, increasing the difficulty to assign some
patients to subtypes.
Furthermore the empirically assigned classification is probably
more informative on the pathophysiology of specific PD symp-
toms but it could also hamper a global view on complex clinical
patterns of motor and non-motor symptoms that characterize
PD patients. Since data driven subtypes reviewed elsewhere (van
Rooden et al., 2010), this review aims at presenting an overview
of some of the main PD subtypes derived from the empirically
assigned classification; we briefly present their neural and behav-
ioral correlates to show how these subtypes may correlate with
each other. For this purpose in the next sections we describe
the following subtypes: motor (postural instability and gait dif-
ficulty vs. tremor) and non-motor symptoms (mild cognitive
impairment (MCI) vs. dementia; with/without ICD, depression,
or hallucinations). Next, we briefly discuss existing data on how
these subtypes correlate with each other.
COGNITIVE SUBTYPES IN PD: FROMMILD COGNITIVE
IMPAIRMENT TO DEMENTIA
Since the early clinical stages, PD patients present an increased
risk of cognitive impairment, with prevalences of MCI rang-
ing from 14.8–18.9% in newly diagnosed drug-naïve patients
(Aarsland et al., 2009, 2010; Poletti et al., 2012a,b), up to a 50%
and 5 years after clinical diagnosis (Broeders et al., 2013).
MCI may be diagnosed when a neuropsychological impair-
ment is demonstrated by performances 1–2 standard deviations
below appropriate norms in at least two tests of the same cog-
nitive domain (MCI single domain; for example dysexecutive
MCI when only the executive domain is impaired; amnestic MCI
when only episodic memory is impaired) or in at least one test
in two different cognitive domains (MCI multiple domains: for
example executive and episodic memory domains or executive
and visuospatial domains are impaired) and there is a preserved
functional level in everyday activities, not considering difficulties
related to the motor symptoms (Litvan et al., 2012).
In the early clinical stage, cognitive impairment in PD is pri-
marily characterized by deficits if executive functions, caused by
loss of dopaminergic neurons in the nigrostriatal pathway (Kish
et al., 1988) and resulting in the reduction of dopamine levels
in the striatum. This dopamine reduction negatively impacts
the functioning of the dorsolateral frontostriatal loop (linking
dorsolateral prefrontal cortex, dorsolateral caudate nucleus of
the striatum, dorsomedial globus pallidus and thalamus), which
is mainly involved in of executive functions such as working
memory, planning and set-shifting (Alexander et al., 1986) and
dopaminergic drugs have a beneficial effects on these functions in
the early stages of disease by impacting striatal dopamine levels
(Cools, 2006).
The presence of MCI since the early PD stages is associated not
only with the frontostriatal deficit but also with an early involve-
ment of parietal and occipital cortices (Pappata et al., 2011); this
finding have been consistently reported in patients with MCI by
structural neuroimaging studies, detecting atrophic changes in a
number of cortical regions, including occipital, parietal, medial
temporal and prefrontal cortices (Song et al., 2011; Weintraub
et al., 2011a; Lee et al., 2012a) and cortical hypometabolism in
frontostriatal loops and parietal and occipital regions (Nobili
et al., 2011; Ekman et al., 2012; Garcia-Garcia et al., 2012; Nagano-
Saito et al., 2013).
Advanced PD stages, usually presenting dementia in 75–
80% of patients (Aarsland et al., 2003; Williams-Gray et al.,
2013), are characterized by widespread cortical and subcortical
atrophic changes (Burton et al., 2004; Nagano-Saito et al., 2005;
Summerfield et al., 2005; Beyer et al., 2007; Weintraub et al.,
2011b; Melzer et al., 2012) and more severe temporal, parietal
and occipital hypometabolism in comparison with MCI patients
(Garcia-Garcia et al., 2012).
In sum, the cognitive profile of PD is usually characterized by
an early executive impairment, a sign of nigrostriatal degenera-
tion, and subsequently by impairment of visuospatial functions,
memory and/or language, a sign of cortical diffusion of Lewy body
pathology, evidenced by cortical atrophy and hypometabolismml:
this second feature in particular, in comparison with the first
one, is associated with an increased risk of developing MCI and
subsequently dementia (Jellinger, 2013; Kehagia et al., 2013).
TREMOR VS. NON-TREMOR IN PD
As discussed above, PD involves a spectrum of motor symptoms
that include akinesia, bradykinesia, and resting tremor, among
others. Few studies categorize the patients into different sub-
groups, depending on the motor symptoms they present. This
usually involves dividing the patients into a tremor-dominant and
non-tremor-dominant groups, with the latter is either patients
with predominant akinesia, bradykinesia, or postural instability
and gait symptoms (Jankovic et al., 1990; Zaidel et al., 2009; Mure
et al., 2011; Schillaci et al., 2011; Lee et al., 2012b; Wylie et al.,
2012). Bradykinesia, and postural instability and gait dysfunction
are more common in patients with a rapid disease progres-
sion compared with PD patients with a slower progression rate
(Jankovic et al., 1990).
Studies have generally shown that PD patients with tremor are
usually less cognitively impaired than PD patients with akinesia
or gait dysfunction (Burn et al., 2006; Lyros et al., 2008; Oh et al.,
2009; Domellof et al., 2011). For example, Vakil and Herishanu-
Naaman (1998) found that tremor-dominant patients are less
impaired at procedural learning tasks than akinesia-dominant
patients. Studies also showed that PD patients with tremor are
less impaired than PD patients with other motor subtypes on
perceptual tasks, including peripheral vision and visual processing
speed (Seichepine et al., 2011). Interestingly, we also found that
akinesia-dominant patients were more impaired than tremor-
dominant patients at various working memory (Moustafa et al.,
2013a) and learning (Moustafa et al., 2013b) measures. Prior
studies have reported significant correlations between bradyki-
nesia severity and cognitive measures in newly diagnosed PD
patients (Domellof et al., 2011; Poletti et al., 2012b). For example,
Domellof et al. (2011) found that bradykinesia scores correlate
with Wisconsin Card Sorting Test, digit span, and Trail Making
Test performance. Along the same lines, (Poletti et al., 2012a,b)
reported a correlation between bradykinesia and Trail Making
Test as well as achieved category in the Modified Card Sorting Test.
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This pattern of results also applies to psychiatric symptoms.
One neuropsychological study found that unlike tremor-
dominant patients, PD patients with non-tremor symptoms
show increased rates of depression, apathy, and hallucinations
(Reijnders et al., 2009). Further, neuropsychological studies found
depression is more common in akinesia-dominant patients than
tremor patients (Starkstein et al., 1998). Recently, a neuropsycho-
logical study found that unlike patients with dominant tremor
symptoms, patients with postural instability and gait deficits show
more impulsive behavior (Wylie et al., 2012). Clinical and neu-
ropsychological studies also suggest that the severity of akinesia
symptoms is a risk factor for the development of dementia and
MCI in PD patients (Poletti et al., 2011; Poletti and Bonuccelli,
2013).
For more than two decades, it has been shown that patient with
dominant akinesia show more neural damage than PD patients
with dominant tremor (Paulus and Jellinger, 1991). Recent neu-
ropsychological studies showed that non-tremor symptoms in
PD, including postural instability and gait deficits, are associated
with grey matter degeneration (Rosenberg-Katz et al., 2013).
Other neuropsychological and animal studies suggest that akine-
sia and bradykinesia are arguably associated with basal ganglia
(and corticostriatal circuits) dysfunction, while tremor is perhaps
associated with cerebellar, thalamic, and subthalamic nucleus
abnormalities (Kassubek et al., 2002; Probst-Cousin et al., 2003;
Weinberger et al., 2009; Zaidel et al., 2009; Mure et al., 2011).
For example, Schillaci et al. (2011) found that PD patients with
akinesia and rigidity as the predominant symptoms have signif-
icantly more widespread dopamine loss in the striatum than PD
patients with tremor as the predominant symptom(also see Eggers
et al., 2011). These results support a relationship between motor
variables (including akinesia and bradykinesia) and cognitive
performance in PD patients.
IMPULSE CONTROL DISORDERS IN PD
Dopaminergic medications, especially some dopamine agonists,
can trigger ICDs, such as hypersexuality, hobbyism, dopamine
dysregulation syndrome, binge eating and pathological gambling,
in a considerable subpopulation of PD patients (Dodd et al., 2005;
Voon et al., 2007). It is also important to note that ICDs can be
caused by other factors beside the administration of dopaminergic
medications. For example, few studies reported the occurrence of
ICDs in drug-naïve PD patients (Antonini et al., 2011). Interest-
ingly, studies also report that some PD patients present either with
single or multiple ICDs, and that each of these subgroups have a
different cognitive and neural profile (Vitale et al., 2011). Further,
few studies have investigated the prevalence and predictors of
ICDs. For example, it was reported that alexithymia is a predictor
of ICDs in PD patients (Goerlich-Dobre et al., 2013). It was
also found that frontal executive function is a predictor of the
occurrence of pathological gambling (Santangelo et al., 2009b).
Prior studies show that ICDs are observed more often in
patients on D2 dopamine agonists (Weintraub et al., 2006; Voon
and Fox, 2007) It is suggested that patients vulnerable to ICDs
have a lower D2 receptor density, even before onset of PD (Dagher
and Robbins, 2009). The density of D2 receptors might fur-
ther decreases in these vulnerable patients by overstimulation of
ventral striatal D2 receptors in PD and increases the rate of ICDs
in such vulnerable patients. Other studies suggest that binding
to dopamine D3 receptors is responsible for the occurrence of
ICDs (Vilas et al., 2012). A recent study found that patients with
ICDs were more likely to be on antidepressant medications and
had more motor complications than those without ICDs (Mack
et al., 2013). In addition to dopaminergic medications, studies
also show that ICDs can be caused by deep brain stimulation
of the subthalamic nucleus (Frank et al., 2007; Callesen et al.,
2013a; but also see Santangelo et al., 2013). Studies also show that
cognitive behavioral therapy can ameliorate ICDs in PD patients
(Okai et al., 2013).
ICDs in PD is also associated with cognitive and psychiatric
symptoms. Unlike patients without ICDs, PD with ICDs show
increased discounting in delay discounting tasks (Housden et al.,
2010; Voon et al., 2010b; Leroi et al., 2013), increased reward
learning (Voon et al., 2011), and impairment performing the
Iowa gambling task (Gescheidt et al., 2012). Studies have also
shown that PD patients with ICDs are more impaired than
patients without ICDs on working memory (Djamshidian et al.,
2010; Voon et al., 2010a), but they did not differ on executive
functioning (Siri et al., 2010). A recent study also showed that PD
patients with ICDs are more impaired at planning and set-shifting
tasks than patients without ICDs (Vitale et al., 2011), although
the study did not include a healthy control group. Another study
showed ICDs in PD are associated with executive dysfunction
(Voon et al., 2010b) and working memory impairment (Voon
et al., 2011). Further, it was found that PD patients with the
hypersexuality subtype show more impairment on the Stroop task
than patients with pathological gambling (Vitale et al., 2011),
suggesting that the different impulsive behaviors are associated
with different behavioral, and potential neural, profile. Studies
also found that ICDs in PD are associated with depression and
irritability (Pontone et al., 2006).
Neural studies have implicated cortical and subcortical struc-
ture for the occurrence of ICDs in PD. Many studies show that the
underlying neural substrates of ICDs in PD are mostly the ventral
striatum, including the nucleus accumbens (Cools et al., 2007;
Dagher and Robbins, 2009; Steeves et al., 2009; Voon et al., 2010a).
For example, using PET imaging, Steeves et al. (2009) found
greater decreases in binding potential in the ventral striatum in
PD patients on dopamine agonists with pathological gambling.
Additionally, (Voon et al., 2010a,b) reported impaired dopamine
signaling in ventral striatal blood oxygen level dependent (BOLD)
in PD patients with ICDs. It has been suggested that restoration of
dopamine transmission in the dorsal striatum might lead to over-
dosing of the ventral striatum which results in excessive dopamine
receptor stimulation in the ventral striatum (Swainson et al., 2000;
Cools et al., 2001) that induce ICDs in some subjects (Cools et al.,
2003; Dagher and Robbins, 2009). A recent study showed that
increase of striatal dopamine might lead to ICDs in PD (Voon
et al., 2013). Studies have also implicated the hippocampus in the
occurrence of ICDs in PD (Calabresi et al., 2013). Beside sub-
cortical structures, neural studies have shown that patients with
ICDs show dopamine reduction in the ventromedial prefrontal
cortex (and nucleus accumbens) compared with those without
ICDs (Lee et al., 2013).
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DEPRESSION IN PD
Depression is one of the most common non-motor symptoms in
PD patients (Schrag et al., 2007; Picillo et al., 2009). It is estimated
that roughly 40% of PD patients show depressive symptoms
(Slaughter et al., 2001; McDonald et al., 2003; Leentjens, 2004;
Schrag et al., 2007; clinical manifestations, etiology, and treatment
of depression in PD). These depressive symptoms include social
withdrawal and anhedonia (inability to experience pleasure).
Depression in PD is often diagnozed as follows: patients with Beck
Depression Inventory (BDI) score greater than 13/14 is considered
in the depression group, while the others are in the non-depressed
group (Leentjens et al., 2000; Schrag et al., 2007; Herzallah
et al., 2010). Furthermore, patients with major depressive disorder
have a threefold higher risk to develop Parkinson’s later in life
(Schuurman et al., 2002). Like ICDs, it is well recognized that
the incidence of depression among PD patients is much higher
than among age-matched healthy participants (Cummings, 1992;
Veiga et al., 2009). Selective serotonin reuptake inhibitors as
well dopamine agonists, such as pramipexole and pergolide were
shown to have antidepressant effects in PD depression (Picillo
et al., 2009).
Research has shown that depressive symptoms in PD have a
negative impact on PD patients’ quality of life (Karlsen et al.,
1999; Schrag et al., 2000). Studies also suggest depression in PD is
associated with intellectual impairment and inattention (Mayeux
et al., 1981). Furthermore, depression in PD is associated with
cognitive impairment (Kuzis et al., 1997; Bader and Hell, 1998;
Errea and Ara, 1999). Current studies in PD patients with depres-
sion largely focus on executive functioning, working memory, or
memory (Kuzis et al., 1997; Norman et al., 2002; Kummer et al.,
2009; Santangelo et al., 2009a). We also found that PD patients
with depression were more impaired at learning tasks than PD
patients without depression (Herzallah et al., 2010).
It debated in the literature which mechanism contributes the
occurrence of depression in PD, and whether depression symp-
toms are related to other psychiatric symptoms in PD, including
apathy and anxiety. Further, it is debated whether depression in
PD are related to dopamingeric dysfunction (Eskow Jaunarajs
et al., 2011). Some also argue that depressive symptoms in PD can
be due to psychosocial factors or secondary to motor impairment
(Aarsland et al., 2012). Further, it is not clear which neuro-
transmitter system dysfunction contributes to PD depression, as
many argue it could be related to dopaminergic, noradrenergic
and/or serotonergic dysfunction (Aarsland et al., 2012). It is also
argued that depressive symptoms are more related to severity of
motor symptoms in PD, particularly akinesia and bradykinesia
(Reijnders et al., 2009).
Neurobiological studies have also investigated the neural sub-
strates of depression in PD. For example, imaging studies found
that patients with PD who develop depression show structural
changes that reflect dopaminergic dysfunction (Walter et al.,
2010). This is in agreement with case reports showing that deep
brain stimulation of the substrania nigra can trigger depressive
symptoms in PD (Bejjani et al., 1999). Other neural studies
suggest that while the primary neural dysfunction of PD is the
dorsal striatum and its dopaminergic afferents (Kish et al., 1988),
depression in PD is associated with deficits in the ventral regions
within striatum, including the nucleus accumbens (Remy et al.,
2005). Interestingly, Voon et al. (2011) argue that depression in
PD (hypoactive state) is perhaps the antithesis of ICDs (hyperac-
tive state). For example, research has shown that depression in
PD can result from reduction of dopamine levels in the brain
(Thobois et al., 2010). This is contrasted from ICDs, which is
often associated with increased dopamine levels, due mostly to the
administration of dopamine agonist therapy (Voon et al., 2007),
but also see Callesen et al. (2013b) for evidence of association of
impulsivity and depression in PD.
It is debated whether depression is caused by motor abnor-
malities or other neuropathology in PD. Imaging studies suggest
that patients with depression who show structural abnormalities
at the level of the substantia nigra are possibly at an elevated risk
of later developing definite PD (Hoeppner et al., 2009; Shen et al.,
2013). Nonmotor manifestations of PD (such as depression) are
the earliest to appear (Simuni and Sethi, 2008).
HALLUCINATIONS IN PD
Psychosis and visual and olfactory hallucinations occurs in
approximately 20–30% of PD patients (Rabey, 2009). In PD
patients, visual hallucinations are more common than auditory
or olfactory hallucinations (Diederich et al., 2009). Psychosis is
usually defined as involving one of the following symptoms: (a)
illusions (misinterpretations of existing stimuli), hallucinations
(defined as hallucinatory symptoms), and/or delusional symp-
toms. Psychosis in PD is usually confirmed using the Parkinson’s
Psychosis Rating Scale (Friedberg et al., 1998). Although it was
previously found that the administration of dopaminergic drugs
is the main cause of psychosis and hallucinations (Morgante et al.,
2012), recent studies additionally show that sleep disturbance,
dementia, longer disease duration, and advanced stage of the
disease, can also exacerbate psychotic symptoms in PD patients
(Poewe, 2003; Fenelon et al., 2006; Fenelon, 2008; Bannier et al.,
2012; Gibson et al., 2013; Lee and Weintraub, 2012; Morgante
et al., 2012). So unlike earlier clinical practice, a diagnosis of
psychosis in PD is made when the patients have not had any
dopaminergic medications. Among risk factors, one longitudinal
study found that frontal dysfunction was also a predictor for the
development of hallucinations in PD (Santangelo et al., 2007).
Prior reports also suggest that hallucinations in PD patients
are the main reason for admission to nursing homes (Diederich
et al., 2009). Psychosis in PD is also a risk factor for the occur-
rence of severe cognitive dysfunctions such as dementia (Factor
et al., 2003) and is associated with a diminished quality of life
(Zahodne and Fernandez, 2008; Rabey, 2009). Prior studies have
shown strong links between medication dosage, dementia, sleep
disturbance, and psychosis in PD patients (Poewe, 2003; Fenelon,
2008; Bannier et al., 2012; Gibson et al., 2013).
There have been very few studies investigating the percep-
tual and cognitive correlates of psychosis in PD. Studies gener-
ally report cognitive and behavioral dysfunction in PD patients
with psychosis than in patients without psychosis (Baydas et al.,
2005; Shine et al., 2011). For example, studies have shown that
PD patients with hallucinations are more impaired than PD
patients without hallucination on recognition memory (Barnes
et al., 2003), executive function (Grossi et al., 2005), frontal
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function (as measured using the frontal assessment battery),
attentional processes (Meppelink et al., 2008), and semantic flu-
ency (Ramirez-Ruiz et al., 2006). Specifically, Botha and Carr
(2012) argue that the gating of irrelevant information to working
memory is the mechanism underlying the occurrence of hal-
lucinations. Prior studies have shown that hallucinations and
psychosis in PD patients are associated with visual disturbance
(Gallagher and Schrag, 2012; Shine et al., 2012). Behavioral
differences between PD patients with and without psychosis can
be observed during the performance of complex perceptual tasks
(Shine et al., 2011).
Prior studies suggest that hallucinations in PD patients can
be due to either cortical or subcortical atrophy (Papapetropoulos
et al., 2006). Specifically, psychosis and hallucinations can stem
from dysfunction to either the prefrontal cortex (Corlett et al.,
2007; Fletcher and Frith, 2008), basal ganglia (Frank, 2008;
Howes et al., 2012), or hippocampal region (Bogerts et al.,
1985; Weinberger, 1999; Goldman and Mitchell, 2004; Keri, 2008;
Grace, 2010). Studies also report temporal lobe dysfunction in
PD patients with visual hallucination (Botha and Carr, 2012) and
also with studies showing that early onset of hallucinations in PD
patients is associated with dysfunction to the parahippocampus
and inferior temporal cortex (Harding et al., 2002). It was found
that carrying the APOE 4 allele, which is associated with a
small hippocampal volume in healthy older subjects (Alexopoulos
et al., 2011), is also a risk factor for the development of psychotic
episodes in PD patients (de la Fuente-Fernandez et al., 1999;
Goldman et al., 2004; Feldman et al., 2006).
DISCUSSION: RELATIONSHIPS AMONG PD SUBTYPES
In the previous sections we briefly reviewed some clinical sub-
types of PD derived from the empirically assigned classification
approach, that has the advantage of describing a small number
of subtypes as regards specific clinical symptoms, with ease of
implementation and assignment of patients to one or another
subtype. On the other hand, because of inability to investigate
relationships between subtypes, this approach does not provide a
global view on complex clinical patterns of motor and non-motor
symptoms.
This study aimed at reviewing most common PD subtypes
derived from the empirically assigned classification to attempt a
possible integration of them, through the identification of their
possible relationships and their possible common neuropatho-
logical causes Indeed the clinical heterogeneity of PD lead to the
classification in many subtypes as regards motor symptoms (e.g.,
postural instability and gait difficulty vs. tremor), cognition (MCI
vs. dementia), psychopathological features (e.g., with ICD vs.
without ICD; with psychosis vs. without psychosis), demographic
features (e.g., young onset vs. late onset) and disease features (e.g.,
rapid progression vs. slow progression).
A first issue involves the relationship between motor sub-
types and subtypes of non-motor symptoms, in particular of
the cognitive and psychopathological domains. The non-tremor
dominant motor subtype usually presents a more severe clinical
pattern of non-motor symptoms in comparison to the tremor
dominant subtype. Since the early untreated stages of PD, this
subtype is characterized by a higher risk of MCI (Poletti et al.,
2012a) and longitudinally is associated with faster motor wors-
ening (Vu et al., 2012), cognitive decline (Burn et al., 2006), and
higher risk of developing dementia (Alves et al., 2006; Sollinger
et al., 2010). This subtype is also associated with an increasing
risk of developing psychopathological features, including affective
features such as depression and alexithymia (Starkstein et al.,
1998; Reijnders et al., 2009; Poletti et al., 2011; Burn et al.,
2012) and psychotic features as hallucinations (Reijnders et al.,
2009). Conversely, the tremor dominant subtype appears to be
characterized by a less severe clinical picture, with a slower pro-
gression of motor and cognitive symptoms and a lower risk of
developing dementia and psychopathological features. The more
severe clinical picture of the non-tremor dominant PD subtypes is
due to a more severe Lewy body neuropathological load, as found
at the post-mortem pathological examination (Selikhova et al.,
2009) and a more severe gray matter atrophy of cortical and limbic
structures, as indicated by neuroimaging studies (Rosenberg-Katz
et al., 2013).
A second issue is regarding the relationship between cogni-
tive subtypes and psychopathological subtypes. Few empirical
findings are available from studies based on the classification
of cognitive subtypes: only two studies directly compared cog-
nitive subtypes of PD patients in relation to other non-motor
subtypes. One study compared 54 cognitively preserved patients,
48 PD patients with MCI and 25 PD patients with dementia
(Leroi et al., 2012). Apathy was reported in almost 50% of
MCI patients and PD patients with dementia, and was the only
psychopathological manifestation differentiating cognitively pre-
served patients from MCI patients. Moreover the prevalence of
psychotic symptoms as hallucinations and delusion progressively
increased according to the degree of cognitive impairment (12.9%
in cognitively preserved, 16.7% in MCI and 48% in PD patients
with dementia). Another study compared different subtypes of
MCI (Goldman et al., 2012) in 128 PD patients with MCI;
according to the cognitive profile patients were classified as non-
amnestic single domain (47.7% of the sample), amnestic multiple
domain (24.2%), amnestic single domain (18.8%), and non-
amnestic single domain, and executive functions and visuospa-
tial functions were the most frequently impaired domains. In
comparison to other subtypes, non-amnestic multiple domain
MCI patients showed most pronounced difficulties with pos-
tural instability and gait; subtypes did not differ in relation
to age, PD duration, medication use, mood or behavioral
disturbances.
These few findings are in agreement with the more robust
empirical literature on the classification in psychopathological
subtypes, suggesting that different subtypes may present different
clinical patterns along the disease course. The subtype character-
ized by affective features (e.g., depression, apathy and anxiety)
is very common at each disease stage, because it is associated
with several non-disease specific risk factors (Leentjens et al.,
2013); moreover it is also associated with the executive impair-
ment (Poletti et al., 2012a), and it is only partially modified by
dopaminergic therapies (Eskow Jaunarajs et al., 2011).
Different patterns characterize psychotic features as hallucina-
tions and delusions. Hallucinations may be present in patients
with MCI (Shin et al., 2012; Hepp et al., 2013) but are particularly
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prevalent in advanced PD stages, in association with dementia
(Rana et al., 2012) and with cortical atrophy at neuroimaging
(Papapetropoulos et al., 2006). Delusions also may be associated
with hallucinations and dementia in advanced patients but may
be present in isolation in cognitively preserved patients, probably
due to the interaction between individual susceptibility (as psy-
chiatric familial history) and dopaminergic therapy (Poletti et al.,
2012a).
ICD are more in common in patients without dementia than
in patients with dementia (9.6% vs. 3.8% in a recent cross-
sectional study: Poletti et al., 2013). However, an impairment
of both orbitofrontal and dorsolateral executive functions may
represent a risk factor (Poletti and Bonuccelli, 2012) and probably
interplays with individual (premorbid level of impulsivity), phar-
macological (dopamine agonist therapy) and disease related (stri-
atal dopaminergic alteration) risk factors (Dagher and Robbins,
2009).
A controversial issue involving motor, cognitive and psy-
chopathological PD subtypes regards the possible influence of
the side of motor onset. Empirical findings principally involve
cognition: the side of motor onset does not influence cognition in
newly diagnosed untreated patients (Erro et al., 2013; Poletti et al.,
2013); in patients “on” dopaminergic therapy a right-side motor
symptom predominance is typically associated with difficulties in
tasks of language and verbal memory, whereas a left-side motor
symptom predominance is typically associated with difficulties in
visuospatial tasks (Verreyt et al., 2011). More heterogeneous and
controversial are findings on the role of the side of motor onset on
motor subtypes (e.g., Stewart et al., 2009; Baumann et al., 2013)
and especially on psychopathological subtypes (e.g., Foster et al.,
2011; Dewey et al., 2012), therefore more empirical studies are
needed on this issue.
Further empirical studies are also needed on other clinical
features that have been scarcely investigated in relation to motor,
cognitive and psychopathological subtypes. For example, data
driven classification methods (van Rooden et al., 2010) suggested
that PD patients could be also classified as “rapid disease pro-
gression” vs. “slow disease progression” or according to age of
PD onset (e.g., young vs. late onset); in this perspective these
features could be investigated by studies based on empirically
assigned classifications. Moreover also other features suggested
by empirically assigned classifications, as freezing of gait and
autonomic dysfunctions, should be investigated in relation to
motor, cognitive and psychopathological subtypes.
In sum, all these psychopathological subtypes may be present
in all disease stages, and the presence of cognitive impairment
represents a risk factor for their occurrence. Overall, PD is a het-
erogeneous disorder encompassing many subtypes along motor,
cognitive, and psychiatric dimensions. Further, as discussed here,
some of these subtypes are related (e.g., isolated delusions and
ICD are more common in patients without dementia while hallu-
cinations are more common in patients with dementia).
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